Dr. Ribhi Shawar currently serves as the Branch Chief at the Division of Microbiology in the Office of In vitro Diagnostic and Radiological Health (OIR) at the Center for Devices and Radiological Health (CDRH) at FDA where he specializes in the area of antimicrobial susceptibility testing and detection of resistance. Dr. Shawar has a Ph.D. in Medical Microbiology and an M.Sc. in Medical Parasitology. He is a certified diplomate by the American Board of Medical Microbiology (ABMM) for 25 years. Dr. Shawar is a recognized clinical microbiologist with diverse experience in hospital settings, diagnostic and pharmaceutical microbiology and anti-infective drug development with strong knowledge in regulatory aspects both in antimicrobial drug products and infectious disease diagnostics. Dr. Shawar has authored multiple publications in peer reviewed journals, served or currently serves as advisor to several CLSI Sub-committees and is the recipient of multiple awards including GSK Gold Award. He served for two terms as Chair of the ABMM Standards and Examinations Committee (Parasitology) and as member of the editorial board of the Journal of Clinical Microbiology. Prior to joining FDA, Dr. Shawar served in multiple roles at various institutions including Baylor College of Medicine, VA Medical Center in Houston, PathoGenesis Corporation, Chiron (Novartis) in Seattle, and GlaxoSmithKline in Philadelphia.
Dr. Shawar will be speaking at World Anti-Microbial Resistance Congress USA 2016 about ‘FDA Perspective: Methods to detect antimicrobial susceptibility and resistance’. This session will cover FDA initiatives to promote development of new assays, defining “Rapid”: aspects of growth-dependent and growth-independent diagnostic assays, and the role of new assays in antimicrobial drug trials. To hear from Dr. Ribhi Shawar and more industry experts, attend World Anti-Microbial Resistance Congress USA 2016, held September 8-9 in Washington, DC.